THE DEAL, AT A GLANCE
From the announcementNewLimit
01What it doesBrian Armstrong's NewLimit is a Digital Health company focused on human trials.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by Founders FundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedNewLimit raised $435M Series C, announced 2026-06-03From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersNewLimit's Series C financing positions the company to advance its Digital Health strategy around human trials.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
NewLimit · Financing Record
Explore source-linked visual explanations for NewLimit. Unsupported claims are withheld while source review continues.
Record 5228 · Recorded date: 2026-06-03
Explore company records →